ASTHMA RESEARCH STUDY – PATIENT OPPORTUNITY

Are you at least 18 years of age, have asthma, and are prescribed an albuterol- or levalbuterol-only short-acting inhaler for rescue use? If so, you may be eligible to participate in a research study aimed at reducing asthma attacks and treating or preventing symptoms of asthma.

 

Study participants will be provided with an FDA-approved asthma rescue inhaler, AIRSUPRA™, for 12 months in place of their current rescue inhaler for asthma treatment.

What is AIRSUPRA™?

AIRSUPRA™ combines two common asthma medicines (albuterol and budesonide) into a single inhaler. Albuterol helps to relax the smooth muscles of the airways, causing the airways to widen, leading to easier breathing. Budesonide helps to decrease inflammation in the lungs. Inflammation in the lungs can lead to breathing difficulties.  

• AIRSUPRA™ is used as two inhalations (puffs), equal to 1 dose, as needed. Do not use more than 12 inhalations (6 doses) in a 24-hour period. 
• AIRSUPRA™ does not replace your current maintenance treatment for asthma.

What is the purpose of the ANCHOR Asthma Clinical Trial?

The primary objective of the ANCHOR asthma clinical trial is to compare asthma exacerbation rate changes after switching to AIRSUPRA™ from an albuterol- or levalbuterol-only short-acting inhaler.

How do I know if I’m eligible to participate in the ANCHOR Asthma Clinical Trial?

You may be eligible if you meet the following criteria:

Inclusion criteria (can participate):

18 years of age or older

 

At least one asthma diagnosis documented in your medical records

 

At least one filled prescription of rescue inhaler for asthma within last 12 months

At least one asthma attack within last 12 months

Have both medical and pharmacy insurance coverage